Synapse - Ana Alarcon Tomas

Results (12)

An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma

Journal Article

Raj, S. S.; Fei, T.; Fried, S.; Ip, A.; Fein, J. A.; Leslie, L. A.; Alarcon Tomas, A.; Leithner, D.; Peled, J. U.; Corona, M.; more...
Nature Medicine (2025)

Fulltext@MSK | Save

CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: Phase 2 trial interim results

Journal Article

Park, J. H.; Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G.; Dahi, P.; Lin, R. J.; Scordo, M.; Perales, M. A.; more...
Nature Medicine (2023)

Fulltext@MSK | Save

Inflammatory biomarker clusters are predictive of response and toxicity in large B-cell lymphoma treated with CD19 CAR-T cell therapy

Meeting Abstract

Raj, S.; Perales, M. A.; Fein, J. A.; Tomas, A. A.; Batlevi, C. L.; De Lapuerta, M. C.; Dahi, P. B.; Danylesko, I.; Fried, S.; Funnell, T.; more...
Blood (2022)

Fulltext@MSK | Save

Vitamin D insufficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Journal Article

Nath, K.; Tomas, A. A.; Flynn, J.; Fein, J. A.; Alperovich, A.; Anagnostou, T.; Batlevi, C. L.; Dahi, P. B.; Fingrut, W. B.; Giralt, S. A.; more...
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

Vitamin D deficiency is associated with inferior clinical outcomes in patients with large B-cell lymphoma receiving anti-CD19 CAR T-cell therapy

Meeting Abstract

Nath, K.; Alarcon Tomas, A.; Flynn, J.; Fein, J. A.; Alperovich, A.; Anagnostou, T.; Batlevi, C. W.; Dahi, P. B.; Fingrut, W.; Giralt, S. A.; more...
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

The Simplified Comorbidity Index: A new tool for prediction of nonrelapse mortality in allo-HCT

Journal Article

Shouval, R.; Fein, J. A.; Cho, C.; Avecilla, S. T.; Ruiz, J.; Alarcon Tomas, A.; Sanchez-Escamilla, M.; Castillo Flores, N.; Yáñez, L.; Barker, J. N.; more...
Blood Advances (2022)

Fulltext@MSK | Save

Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy

Journal Article

Shouval, R.; Alarcon Tomas, A.; Fein, J. A.; Flynn, J. R.; Markovits, E.; Mayer, S.; Afuye, A. O.; Alperovich, A.; Anagnostou, T.; Besser, M. J.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center

Meeting Abstract

Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
Blood (2021)

Fulltext@MSK | Save

Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy

Meeting Abstract

Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
Blood (2021)

Fulltext@MSK | Save

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

Journal Article

Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J. R.; Shouval, R.; Alarcon Tomas, A.; Silverberg, M. L.; Batlevi, C.; Brentjens, R. J.; Dahi, P. B.; Devlin, S. M.; more...
Blood Advances (2021)

Fulltext@MSK | Save